Hironori Yamaguchi

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial

Hironori Ishigami, Yoshiyuki Fujiwara, Ryoji Fukushima et al. · Journal of Clinical Oncology · 2018 · 356 citations

Medicine, Oncology, Pharmacology +13

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 232 citations

Medicine, Oncology, Surgery +11

Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1.

Dai Shida, Joji Kitayama, Hironori Yamaguchi et al. · PubMed · 2003 · 214 citations

Life Sciences, Cell Biology, Oncology +13

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

Shigenobu Emoto, Hironori Ishigami, Hiroharu Yamashita et al. · Gastric Cancer · 2011 · 184 citations

Medicine, Oncology, Pathology +14